AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31

AMARIN CORP PLC\UK

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$11.53+0.21 (+1.86%)

Close on Oct 19, 2026

Market cap: $4.80B
P/E (TTM): –
Dividend yield: –

AMARIN CORP PLC\UK income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	214	229	307	369	583	614	430	229	181	130	82	54	26	–	–	–	–
Cost of Revenue	–	–	–	–	121	131	96	55	45	34	28	20	12	–	–	–	–
Gross Profit	121	81	166	242	462	483	334	175	136	96	54	34	14	–	–	–	–
Research & Development	20	21	22	30	29	39	34	56	47	50	51	50	73	59	22	28	21
Selling, General & Admin	115	152	200	304	408	463	324	227	135	111	101	79	124	58	23	–	–
General & Administrative	44	38	53	75	–	–	–	–	–	–	–	–	–	58	23	17	13
Operating Expenses	171	173	233	348	451	502	358	283	182	161	152	130	197	117	44	45	34
Operating Income	-50	-92	-68	-106	11	-20	-24	-108	-46	-66	-98	-96	-182	-117	-44	-45	-34
Interest Expense	0.01	0.01	0.01	0.02	0.13	2.61	6.63	8.87	9.77	19	20	19	34	18	0.00	0.02	2.83
Interest & Investment Income	11	13	12	2.82	1.22	4.90	8.50	1.07	0.43	0.23	0.13	0.10	0.34	0.54	0.23	0.05	0.20
Other Non-Operating Income	3.28	1.20	2.06	-0.74	-0.30	0.10	-0.08	-0.33	0.07	-0.48	-0.23	3.73	-1.19	-0.43	-0.01	0.13	0.03
Merger & Restructuring Charges	36	0	11	14	14	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	-0.05	–	–	–	–	–	–	–
Pretax Income	-36	-77	-54	-104	11	-17	-22	-116	-55	-76	-118	-59	-169	-170	-67	-250	-32
Income Tax Expense	2.75	4.98	5.44	2.00	3.56	0.75	0.16	0.10	13	9.97	-3.09	-2.84	-3.19	9.12	2.52	-0.50	-0.90
Net Income incl. Noncontrolling Interests	-39	-82	-59	-106	7.73	-18	-23	-116	-68	-86	–	–	–	–	–	–	–
Net Income	-39	-82	-59	-106	7.73	-18	-23	-116	-68	-86	-115	-56	-166	-179	-69	-250	-31
Net Income to Common	-39	-82	-59	-106	7.73	–	–	–	-68	-86	-149	-56	-166	-179	-69	–	–
EPS (Basic)(per share)	-0.09	-0.20	-0.15	-0.26	0.02	-0.05	-0.07	-0.39	-0.25	-0.41	-0.83	-0.32	-1.03	-1.24	-0.53	-2.49	-0.72
EPS (Diluted)(per share)	-0.09	-0.20	-0.15	-0.26	0.02	-0.05	-0.07	-0.39	-0.25	-0.41	-0.83	-0.36	-1.28	-1.24	-0.53	-2.49	-0.72
Shares Outstanding (Basic, Weighted)(shares)	415	411	408	401	396	382	343	297	271	212	181	174	161	144	0.13	–	–
Shares Outstanding (Diluted, Weighted)(shares)	415	411	408	401	402	382	343	297	271	212	181	174	167	144	0.13	–	–
EBITDA	–	–	–	–	–	–	–	-108	-45	-65	-98	-96	-182	-117	-44	-45	-33

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 42.0%
Operating margin: -21.9%
Net margin: -14.6%
Return on equity, FY2025: -8.2%

Financial strength

Current ratio: 3.67
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 87.4%

Valuation

P/E ratio: –
Price to sales: 25.78
Price to book: 10.82
Dividend yield: –